ALBT

Avalon GloboCare is a company with no business to value. FY2025 revenue was exactly $0.00 — a 100% collapse from the ~$1.3M it had eked out annually since 2021 — after it redeemed its 40% Lab Services MSO stake in Feb 2025 and suspended all cellular-therapy R&D 'to preserve cash.' Against that vanished top line it lost $18.3M, drove the accumulated deficit to -$106M, and burned operating cash of -$4.58M. The auditor has issued an explicit going-concern paragraph, and management concedes survival 'depends on our ability to obtain additional equity or debt financing' — a solvency problem, not a growth problem.

The balance sheet confirms the distress. Cash is down to $109K (-95.9%), current assets of $1.5M sit against $14.1M of current liabilities — a ~$12.6M working-capital hole — and equity of $9.23M is essentially the residual of $23.4M assets over $14.2M liabilities that a going concern casts doubt on. ROE is -197.8%. Meanwhile shares outstanding jumped 385.8% to 8.02M in a single year; with a -$5.64 diluted EPS and a $0.28 quote, the pattern is repeated dilutive financing to fund losses, and the equity math points to prior reverse splits. Existing holders are being ground down.